QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 0.0521
-- x --
-- x --
-- - --
$ 0.04 - $ 0.14
144,356
na
2.3M
$ -5.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-21-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-28-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-17-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-13-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 03-30-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-08-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-13-2018 06-30-2018 10-Q
26 05-04-2018 03-31-2018 10-Q
27 03-14-2018 12-31-2017 10-K
28 11-01-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-10-2017 12-31-2016 10-K
32 11-08-2016 09-30-2016 10-Q
33 08-01-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-11-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-01-2015 03-31-2015 10-Q
39 03-06-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendiant-capital-maintains-buy-on-biolase-lowers-price-target-to-2

Ascendiant Capital analyst Edward Woo maintains Biolase (OTC:BIOL) with a Buy and lowers the price target from $3.5 to $2.

 benchmark-reiterates-speculative-buy-on-biolase-maintains-04-price-target

Benchmark analyst Bruce Jackson reiterates Biolase (OTC:BIOL) with a Speculative Buy and maintains $0.4 price target.

 biolase-to-delist-from-nasdaq
BIOLASE To Delist from Nasdaq
06/18/2024 20:06:50

 benchmark-reiterates-speculative-buy-on-biolase-maintains-04-price-target

Benchmark analyst Bruce Jackson reiterates Biolase (NASDAQ:BIOL) with a Speculative Buy and maintains $0.4 price target.

 biolase-q1-2024-adj-eps-036-misses-017-estimate-sales-10131m-beat-9996m-estimate

Biolase (NASDAQ:BIOL) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.17) by ...

 ascendiant-capital-maintains-buy-on-biolase-lowers-price-target-to-4

Ascendiant Capital analyst Edward Woo maintains Biolase (NASDAQ:BIOL) with a Buy and lowers the price target from $15 to $4.

 why-cutera-shares-are-trading-lower-by-over-26-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected four...

 benchmark-maintains-speculative-buy-on-biolase-lowers-price-target-to-04

Benchmark analyst Bruce Jackson maintains Biolase (NASDAQ:BIOL) with a Speculative Buy and lowers the price target from $2.5...

 dow-dips-200-points-nike-shares-fall-after-q3-results

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points. The Dow traded down 0....

 why-biolase-shares-are-surging-friday

BIOLASE, Inc. shares rise 31% after better-than-expected FY23 EPS results, strong revenue growth expected in 2024 due to increa...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION